Immune Fitness in Older Adults with Relapsed or Refractory Multiple Myeloma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multicenter, non-interventional study examines how baseline immune fitness relates to treatment outcomes in patients aged 65 and older with relapsed or refractory multiple myeloma who are receiving standard-of-care CAR-T or bispecific antibodies. Researchers will perform multiparametric immunophenotyping on pre-treatment blood samples to assess T-cell differentiation, activation, senescence, exhaustion, and helper T-cell subsets, alongside serum biomarkers. Clinical data including frailty, sarcopenia, response, and toxicities will be collected during routine follow-up to explore associations with immune profiles. The primary aim is to see if baseline immune characteristics predict response at 3 months, with secondary analyses evaluating links to toxicity and other outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥ 65 years old
* Relapsed/refractory multiple myeloma
* Eligible for a CAR-T cell or bispecific antibody therapies

Exclusion Criteria:

* \<65 years old
* Active cancer other than myeloma
* Active AL amyloidosis
* Central nervous system (CNS) involvement

Where it's running

• Institut Jules Bordet
  Anderlecht, Brussels Capital, Belgium Recruiting
• CHU Saint-Pierre
  Brussels, Brussels Capital, Belgium Not yet recruiting
• institut roi albert II
  Woluwe-Saint-Lambert, Brussels Capital, Belgium Not yet recruiting

Study contacts

• Study coordinator: Marie Vercruyssen, MD
• Email: marie.vercruyssen@hubruxelles.be
• Phone: +32497840746

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BCD-248 plus daratumumab in relapsed or refractory multiple myeloma

  This study tests whether adding BCD-248 to daratumumab helps people with relapsed or refractory multiple myeloma who have had prior lines of therapy.

  Recruiting at 16 sites Phase 3 Biocad · Homyel and 15 other locations · NCT07742215

• Infectious complications in blood cancer patients treated with bispecific antibodies

  This study tests how often infections occur in adults with blood cancers who are being treated with bispecific antibodies.

  Recruiting at 2 sites Infanta Leonor University Hospital · Madrid, Madrid and 1 other locations · NCT07609576

• Mapping individual multiple myeloma biology to understand relapse and treatment resistance

  This project will test whether combining clinical records with whole-genome and RNA sequencing plus blood tumor markers in people with multiple myeloma can reveal features that explain relapse and treatment resistance.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bo · NCT07582354

• Multi-omics testing for blood and bone marrow cancers

  This project will test a multi-omics lab approach on bone marrow, blood, biopsy and other fluid samples from people with suspected or known hematologic cancers to see if it can better characterize their disease.

  Recruiting Azienda Ospedaliero-Universitaria di Parma · Parma, PR · NCT07445438

• Anonymizing and combining past clinical, genetic, and imaging data from people with multiple myeloma to build AI prediction models.

  This project will try to use already-collected clinical, genetic, and imaging data from adults with multiple myeloma to build AI models that predict disease progression and treatment response, with no new visits or tests required.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bo · NCT07283224

• e-Motion: Promoting Emotion Regulation for People Living with Chronic Cancer

  This pilot tests two emotion-regulation programs—a guided self-help program and a combined group plus guided self-help program—for people recently diagnosed with metastatic or other chronic cancers.

  Recruiting Université Libre de Bruxelles · Brussels, Anderlecht and 1 other locations · NCT07236021

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.